Replimune

Replimune Plunges as FDA Rejection Forces Drastic Restructuring

Brett Shapiro - April 12, 2026

Replimune Faces Pivotal FDA Verdict on Skin Cancer Therapy

angelina - April 1, 2026

Replimune’s Pivotal FDA Verdict Approaches as Cash Runway Extends

angelina - February 9, 2026

Replimune Stock at a Crossroads: Insider Sales and Regulatory Hurdles Shape Outlook

kashif hafeez - December 12, 2025